应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ALC Alcon Inc
交易中 07-10 14:13:26 EDT
89.08
+2.09
+2.40%
最高
89.46
最低
87.58
成交量
104.80万
今开
87.74
昨收
86.99
日振幅
2.17%
总市值
441.57亿
流通市值
440.59亿
总股本
4.96亿
成交额
9,290万
换手率
0.21%
流通股本
4.95亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
爱尔康收购全球首款且唯一干性黄斑病变光疗技术
医疗器械创新网 · 07-08 08:31
爱尔康收购全球首款且唯一干性黄斑病变光疗技术
恒瑞干眼病创新药获批上市,百亿眼科赛道鏖战升级
新浪医药 · 07-04
恒瑞干眼病创新药获批上市,百亿眼科赛道鏖战升级
爱尔康公司获得FDA批准,使用Tryptyr治疗干眼症Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease
动脉网 · 05-30
爱尔康公司获得FDA批准,使用Tryptyr治疗干眼症Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease
爱尔康2025财年第一财季实现净利润3.50亿美元,同比增加41.13%
市场透视 · 05-19
爱尔康2025财年第一财季实现净利润3.50亿美元,同比增加41.13%
爱尔康盘中异动 早盘股价大跌5.03%
市场透视 · 05-14
爱尔康盘中异动 早盘股价大跌5.03%
优趣汇与爱尔康达成合作,览见更精彩的世界
中金在线 · 05-08
优趣汇与爱尔康达成合作,览见更精彩的世界
爱尔康2024财年实现净利润10.18亿美元,同比增加4.52%
市场透视 · 03-03
爱尔康2024财年实现净利润10.18亿美元,同比增加4.52%
爱尔康2024年第四季度每股收益$0.72超出预期$0.71,销售额$24.77亿超出预期$24.66亿
财报速递 · 02-25
爱尔康2024年第四季度每股收益$0.72超出预期$0.71,销售额$24.77亿超出预期$24.66亿
中国建筑第八工程局取得便于ALC条板下挂的装置专利,有利于避免掉落伤人且重量轻等
金融界 · 01-25
中国建筑第八工程局取得便于ALC条板下挂的装置专利,有利于避免掉落伤人且重量轻等
Keybanc:维持Alcon(ALC.US)评级,由增持调整至增持评级, 目标价由107.00美元调整至105.00美元。
金融界 · 01-24
Keybanc:维持Alcon(ALC.US)评级,由增持调整至增持评级, 目标价由107.00美元调整至105.00美元。
爱尔康盘中异动 大幅上涨5.01%报88.60美元
市场透视 · 01-21
爱尔康盘中异动 大幅上涨5.01%报88.60美元
伍晓鹰:中国经济转型内生的制度挑战
北大国发院 · 2024-12-10
伍晓鹰:中国经济转型内生的制度挑战
爱尔康2024财年第三财季实现净利润2.63亿美元,同比增加28.92%
市场透视 · 2024-11-19
爱尔康2024财年第三财季实现净利润2.63亿美元,同比增加28.92%
爱尔康盘中异动 早盘大幅下跌5.17%报87.51美元
市场透视 · 2024-11-12
爱尔康盘中异动 早盘大幅下跌5.17%报87.51美元
PPT抄电影?马斯克和华纳的Cybercab被告上法庭
观察者网 · 2024-10-22
PPT抄电影?马斯克和华纳的Cybercab被告上法庭
欧康维视生物-B午后涨超4% 与爱尔康完成股权与产品交割
金融界 · 2024-10-18
欧康维视生物-B午后涨超4% 与爱尔康完成股权与产品交割
港股异动 | 欧康维视生物-B(01477)涨超3% 与爱尔康完成股权与产品交割
智通财经 · 2024-10-18
港股异动 | 欧康维视生物-B(01477)涨超3% 与爱尔康完成股权与产品交割
欧康维视生物与爱尔康完成股权与产品交割 携手共拓眼科医疗蓝海
中国财富通 · 2024-10-17
欧康维视生物与爱尔康完成股权与产品交割 携手共拓眼科医疗蓝海
加载更多
公司概况
公司名称:
Alcon Inc
所属市场:
NYSE
上市日期:
--
主营业务:
Alcon Inc.最初于1971年在瑞士注册成立。Alcon是一家以研发为主导的全球医疗专业公司,主要专注于眼部护理。该公司开发,生产和销售药品,手术设备和设备以及消费者眼部护理产品。该公司广泛的产品系列是眼科行业中最强大的产品组合之一,在所有主要产品类别中都拥有高质量和技术先进的产品。该公司相信它拥有全球任何公司眼科研究和开发的最大承诺。
发行价格:
--
{"stockData":{"symbol":"ALC","market":"US","secType":"STK","nameCN":"Alcon Inc","latestPrice":89.08,"timestamp":1752171199574,"preClose":86.99,"halted":0,"volume":1048029,"delay":0,"floatShares":494599099,"shares":495700000,"eps":2.250025,"marketStatus":"交易中","change":2.09,"latestTime":"07-10 14:13:26 EDT","open":87.74,"high":89.46,"low":87.575,"amount":92898673.95828,"amplitude":0.021669,"askPrice":89.11,"askSize":100,"bidPrice":89.08,"bidSize":110,"shortable":3,"etf":0,"ttmEps":2.250025,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1752177600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":86.99,"dividendRate":0.003847,"preHourTrading":{"tag":"盘前","latestPrice":87.77,"preClose":86.99,"latestTime":"09:29 EDT","volume":10150,"amount":894601.512,"timestamp":1752154194085},"postHourTrading":{"tag":"盘后","latestPrice":86.98,"preClose":86.98,"latestTime":"18:01 EDT","volume":9886,"amount":859884.29,"timestamp":1752098507211},"volumeRatio":0.725639,"impliedVol":0.254,"impliedVolPercentile":0.38},"requestUrl":"/m/hq/s/ALC","defaultTab":"news","newsList":[{"id":"2549851424","title":"爱尔康收购全球首款且唯一干性黄斑病变光疗技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2549851424","media":"医疗器械创新网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549851424?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:31","pubTimestamp":1751963465,"startTime":"0","endTime":"0","summary":"爱尔康宣布将收购眼科光疗创新企业LumiThera及其用于治疗早中期干性年龄相关性黄斑变性的PBM光生物调节治疗设备---VALEDA。VALEDA是目前唯一被证实能有效改善早中期干性AMD患者基线视力的治疗装置。爱尔康本次收购主要是收购LumiThera的VALEDA,而LumiThera其它业务AdaptDx、Nova/Diopsys将被剥离,继续由LumiThera股东的新公司运营。本次收购预计今年第三季度完成。在LIGHTSITE 3试验中,Valeda达到了主要终点,且被证明是安全有效的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163516a69cbc53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU1852331112.SGD","LU2250418816.HKD","BK4566","LU1989764664.SGD","BK4534","BK4585","LU0198837287.USD","ALC","BK4512","LU1923623000.USD","LU1064131342.USD","LU1242518857.USD","LU0823434583.USD","LU1951200564.SGD","BK4575","BK4529","LU1803068979.SGD","BK4614","LU2265009873.SGD","LU1316542783.SGD","LU1988902786.USD","LU0823421333.USD","LU2360106780.USD","BK4573","LU1303367103.USD","LU0823434740.USD","LU0056508442.USD","LU2098885051.SGD","IE0009356076.USD","IE00BMPRXR70.SGD","LU1880398471.USD","PBM","LU1242518931.SGD","LU2264538146.SGD","BK4543","LU0082616367.USD","BK4198","IE0004445239.USD","LU1951198990.SGD","LU2458330169.SGD","IE00B5949003.HKD","LU0979878070.USD","LU0081259029.USD","LU1880398554.USD","BK4532","BK4139","LU0889565833.HKD","BK4605"],"gpt_icon":1},{"id":"2548396512","title":"恒瑞干眼病创新药获批上市,百亿眼科赛道鏖战升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2548396512","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548396512?lang=zh_cn&edition=full","pubTime":"2025-07-04 19:28","pubTimestamp":1751628507,"startTime":"0","endTime":"0","summary":"7 月 3 日,NMPA 官网显示,恒瑞医药引进的全氟己基辛烷“SHR8058 滴眼液”获批上市,用于治疗睑板腺功能障碍相关干眼病。此外,与对照组相比,SHR8058 滴眼液组有效缓解干眼症状,包括疼痛、干眼症症状意识、干燥频率等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704201846a72edc32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704201846a72edc32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4198","BK4534","LU2265009873.SGD","06622","ALC","LU1804176565.USD"],"gpt_icon":0},{"id":"2539245496","title":"爱尔康公司获得FDA批准,使用Tryptyr治疗干眼症Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2539245496","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539245496?lang=zh_cn&edition=full","pubTime":"2025-05-30 15:35","pubTimestamp":1748590500,"startTime":"0","endTime":"0","summary":"Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease爱尔康公司生产的Tryptyr获FDA批准用于治疗干眼症May 30, 20252025年5月30日Alcon has received U.S. FDA approval for Tryptyr 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of dry eye disease . Tryptyr is a first-in-class TRPM8 receptor agonist and represents a novel treatment option targeting neuromodulation to stimulate natural tear production..阿尔康公司已获得美国FDA批准,用于治疗干眼病症状的Tryptyr0.003%,该药物曾被称为AR-15512。爱尔康通过其在 2022 年以约 7.7 亿美元收购 Aerie Pharmaceuticals 的交易获得了 Tryptyr。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505301540339507e8e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505301540339507e8e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1804176565.USD","BK4198","BK4534","ALC","LU2265009873.SGD"],"gpt_icon":0},{"id":"2536636059","title":"爱尔康2025财年第一财季实现净利润3.50亿美元,同比增加41.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536636059","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536636059?lang=zh_cn&edition=full","pubTime":"2025-05-20 00:00","pubTimestamp":1747670440,"startTime":"0","endTime":"0","summary":"5月20日,爱尔康公布财报,公告显示公司2025财年第一财季净利润为3.50亿美元,同比增加41.13%;其中营业收入为24.73亿美元,同比增加0.57%,每股基本收益为0.71美元。机构评级:截至2025年5月20日,当前有26家机构对爱尔康目标价做出预测,其中目标均价为105.35美元,其中最低目标价为84.76美元,最高目标价为120.00美元。爱尔康经营两个部门:视力护理部门和外科部门。爱尔康拥有世界上最大的眼科手术设备安装基地之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000105a48443be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520000105a48443be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALC"],"gpt_icon":0},{"id":"2535781430","title":"爱尔康盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535781430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535781430?lang=zh_cn&edition=full","pubTime":"2025-05-14 21:34","pubTimestamp":1747229644,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日21时34分,爱尔康股票出现波动,股价急速下挫5.03%。截至发稿,该股报88.24美元/股,成交量52.5982万股,换手率0.11%,振幅0.80%。爱尔康股票所在的医疗设备行业中,整体跌幅为0.04%。爱尔康公司简介:爱尔康是全球领先的视力护理公司之一。爱尔康经营两个部门:视力护理部门和外科部门。爱尔康拥有Dailies、Total1和Air Optix等品牌,控制着美国约四分之一的隐形眼镜市场。爱尔康拥有世界上最大的眼科手术设备安装基地之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514213404a6df0961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514213404a6df0961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1804176565.USD","BK4198","BK4534","ALC","LU2265009873.SGD"],"gpt_icon":0},{"id":"2533906601","title":"优趣汇与爱尔康达成合作,览见更精彩的世界","url":"https://stock-news.laohu8.com/highlight/detail?id=2533906601","media":"中金在线","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533906601?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:22","pubTimestamp":1746696139,"startTime":"0","endTime":"0","summary":"近日,优趣汇与眼科保健行业的领导品牌爱尔康达成合作,为其隐形眼镜及护理液产品提供多渠道的品牌分析、店铺运营、数字营销、供应链管理等全链路电子商务运营服务,助力爱尔康品牌在中国市场的电商布局与发展。此次优趣汇与爱尔康的合作,是双方在各自领域优势的深度融合。优趣汇将帮助爱尔康优化电商运营策略,提升线上渠道的效率和用户体验,提升其品牌知名度和市场占有率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050817520994f054cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050817520994f054cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","BK4198","ALC","LU1804176565.USD","LU2265009873.SGD"],"gpt_icon":0},{"id":"2516653165","title":"爱尔康2024财年实现净利润10.18亿美元,同比增加4.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516653165?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:00","pubTimestamp":1741017634,"startTime":"0","endTime":"0","summary":"3月4日,爱尔康公布财报,公告显示公司2024财年净利润为10.18亿美元,同比增加4.52%;其中营业收入为99.11亿美元,同比增加4.82%,每股基本收益为2.06美元。机构评级:截至2025年3月4日,当前有23家机构对爱尔康目标价做出预测,其中目标均价为103.29美元,其中最低目标价为90.00美元,最高目标价为115.00美元。爱尔康拥有世界上最大的眼科手术设备安装基地之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000043a25d5c18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000043a25d5c18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALC"],"gpt_icon":0},{"id":"1114892665","title":"爱尔康2024年第四季度每股收益$0.72超出预期$0.71,销售额$24.77亿超出预期$24.66亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1114892665","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114892665?lang=zh_cn&edition=full","pubTime":"2025-02-26 05:38","pubTimestamp":1740519511,"startTime":"0","endTime":"0","summary":"爱尔康报告称,季度每股收益为$0.72,超出分析师一致预期的$0.71,增幅为1.41%。这比去年同期的每股收益$0.70增长了2.86%。以上内容来自Benzinga Earnings专栏,原文如下:Alcon reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.71 by 1.41 percent. This is a 2.86 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $2.477 billion which beat the analyst consensus estimate of $2.466 billion by 0.45 percent. This is a 6.22 percent increase over sales of ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"爱尔康2024年第四季度每股收益$0.72超出预期$0.71,销售额$24.77亿超出预期$24.66亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALC"],"gpt_icon":0},{"id":"2506813828","title":"中国建筑第八工程局取得便于ALC条板下挂的装置专利,有利于避免掉落伤人且重量轻等","url":"https://stock-news.laohu8.com/highlight/detail?id=2506813828","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506813828?lang=zh_cn&edition=full","pubTime":"2025-01-25 14:02","pubTimestamp":1737784953,"startTime":"0","endTime":"0","summary":"金融界2025年1月25日消息,国家知识产权局信息显示,中国建筑第八工程局有限公司取得一项名为“一种便于ALC条板下挂的装置”的专利,授权公告号CN 222375719 U,申请日期为2024年5月。通过天眼查大数据分析,中国建筑第八工程局有限公司共对外投资了259家企业,参与招投标项目5000次,知识产权方面有商标信息111条,专利信息5000条,此外企业还拥有行政许可7589个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/25140247820112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4198","BK0183","LU2265009873.SGD","BK0000","601668","LU1804176565.USD","BK0187","BK0086","ALC","BK0010","BK0006","BK0180","BK0188","BK4534","LU1580142542.USD","BK0196","BK0277","BK0015","LU1781817850.SGD","BK0028"],"gpt_icon":0},{"id":"2506968308","title":"Keybanc:维持Alcon(ALC.US)评级,由增持调整至增持评级, 目标价由107.00美元调整至105.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506968308","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506968308?lang=zh_cn&edition=full","pubTime":"2025-01-25 01:32","pubTimestamp":1737739946,"startTime":"0","endTime":"0","summary":"Keybanc:维持Alcon(ALC.US)评级,由增持调整至增持评级, 目标价由107.00美元调整至105.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/25013247812261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ALC"],"gpt_icon":0},{"id":"2505782621","title":"爱尔康盘中异动 大幅上涨5.01%报88.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505782621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505782621?lang=zh_cn&edition=full","pubTime":"2025-01-22 04:58","pubTimestamp":1737493083,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日04时58分,爱尔康股票出现异动,股价急速上涨5.01%。截至发稿,该股报88.60美元/股,成交量149.936万股,换手率0.30%,振幅2.26%。爱尔康股票所在的医疗设备行业中,整体涨幅为2.20%。爱尔康公司简介:爱尔康是全球领先的视力保健公司之一。爱尔康凭借 Dailies、Total1 和 Air Optix 等品牌控制着美国隐形眼镜市场的四分之一。爱尔康拥有世界上最大的眼科手术设备安装基地之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122045803986e74c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122045803986e74c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2265009873.SGD","ALC","BK4534","BK4198","LU1804176565.USD"],"gpt_icon":0},{"id":"2490804398","title":"伍晓鹰:中国经济转型内生的制度挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2490804398","media":"北大国发院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490804398?lang=zh_cn&edition=full","pubTime":"2024-12-10 19:27","pubTimestamp":1733830020,"startTime":"0","endTime":"0","summary":"题记:2024年10月17日,由北大国发院与社科文献出版社联合主办的北大国发院“承泽论坛”第26期举行。在新书《中国经济发展的新阶段:机会与选择》出版上市之际,特别邀请到全球研究中国经济的多位学者共同研讨中国经济转型的必要性与复杂性。本文根据北大国发院经济学教授伍晓鹰在论坛上的演讲整理。中国经济当前遇到的困难...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OnP4IdlvfxTjDnm2URikXdGer16ojyX2hEBggdRcdYc2sAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OnP4IdlvfxTjDnm2URikXdGer16ojyX2hEBggdRcdYc2sAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241210A08ST500","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241210A08ST500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4534","LU2265009873.SGD","ALC","LU1804176565.USD","BK4198"],"gpt_icon":0},{"id":"2484913779","title":"爱尔康2024财年第三财季实现净利润2.63亿美元,同比增加28.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484913779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484913779?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010420,"startTime":"0","endTime":"0","summary":"11月19日,爱尔康公布财报,公告显示公司2024财年第三财季净利润为2.63亿美元,同比增加28.92%;其中营业收入为24.54亿美元,同比增加5.37%,每股基本收益为0.53美元。机构评级:截至2024年11月19日,当前有26家机构对爱尔康目标价做出预测,其中目标均价为101.43美元,其中最低目标价为85.00美元,最高目标价为116.00美元。爱尔康拥有世界上最大的眼科手术设备安装基地之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180044abcedefe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180044abcedefe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALC"],"gpt_icon":0},{"id":"2483529080","title":"爱尔康盘中异动 早盘大幅下跌5.17%报87.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483529080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483529080?lang=zh_cn&edition=full","pubTime":"2024-11-13 00:00","pubTimestamp":1731427233,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日00时00分,爱尔康股票出现波动,股价快速下跌5.17%。截至发稿,该股报87.51美元/股,成交量96.7863万股,换手率0.20%,振幅4.85%。爱尔康股票所在的医疗设备行业中,整体跌幅为0.68%。爱尔康公司简介:爱尔康是全球领先的视力保健公司之一。爱尔康分为两个部门:视力保健和外科,视力保健包括隐形眼镜、镜片护理解决方案和一套眼部保健产品。爱尔康拥有世界上最大的眼科手术设备安装基地之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111300003398e421fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111300003398e421fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1804176565.USD","LU2265009873.SGD","ALC","BK4534","BK4198"],"gpt_icon":0},{"id":"2477750558","title":"PPT抄电影?马斯克和华纳的Cybercab被告上法庭","url":"https://stock-news.laohu8.com/highlight/detail?id=2477750558","media":"观察者网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477750558?lang=zh_cn&edition=full","pubTime":"2024-10-22 12:59","pubTimestamp":1729573180,"startTime":"0","endTime":"0","summary":"Alcon指控称,在特斯拉的自动驾驶出租车CyberCab展示会上,使用了模仿银翼杀手2049的概念图设计,尽管爱尔康拒绝了华纳兄弟探索公司提出的使用相关素材的请求。当时,特斯拉等要求从电影中提取\"一个标志性的静态图像\",从而让华纳兄弟探索工作室能在Robo Taxi发布日宣传Cybercab。特斯拉、马斯克和华纳兄弟等涉诉方尚未对爱尔康的诉讼发表意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410221301269f5572f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410221301269f5572f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4099","BK4533","IE00BSNM7G36.USD","LU0082616367.USD","LU0234570918.USD","LU0820562030.AUD","LU0316494557.USD","LU1720051017.SGD","PPT","LU0056508442.USD","LU0053666078.USD","LU0823414478.USD","LU1145028129.USD","SG9999015986.USD","ALC","BK4511","LU1914381329.SGD","BK4527","BK4588","LU0348723411.USD","LU1861558580.USD","LU1551013342.USD","LU0466842654.USD","BK4551","LU2265009873.SGD","LU1551013425.SGD","LU1429558221.USD","LU0097036916.USD","LU0198837287.USD","BK4581","LU0943347566.SGD","TSLA","LU0823411888.USD","BK4548","LU2213496289.HKD","BK4550","LU2326559502.SGD","BK4592","LU2756315664.SGD","LU2087621335.USD","SG9999015952.SGD","SG9999015978.USD","LU2063271972.USD","LU1861559042.SGD","LU1548497426.USD","LU1720051108.HKD","IE00BJLML261.HKD","IE00BWXC8680.SGD","LU2602419157.SGD"],"gpt_icon":1},{"id":"2476447313","title":"欧康维视生物-B午后涨超4% 与爱尔康完成股权与产品交割","url":"https://stock-news.laohu8.com/highlight/detail?id=2476447313","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476447313?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:19","pubTimestamp":1729228740,"startTime":"0","endTime":"0","summary":"欧康维视生物-B午后上涨4.39%,现报6.18港元,成交额507.15万港元。10月17日,欧康维视生物-B宣布,经2024年第一次临时股东大会审议通过,公司与全球眼健康领域的引领者Alcon Inc.(简称“爱尔康”)成功完成了股权与产品交割。根据协议,欧康维视从爱尔康获得了8款产品组合在中国的研发、制造和商业化领域的相关权益。有业内人士指出,此次交割的顺利完成,不仅丰富了欧康维视的产品管线,更显著增厚了公司在干眼等眼科重要细分领域的产品布局。通过收购这些产品,欧康维视预计将能够提供更全面和先进的治疗方案,进一步满足患者需求并扩大市场份额。\n\n\r\n 责任编辑:栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/18131944148727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01477","LU1804176565.USD","BK4534","LU2265009873.SGD","ALC","BK1574","BK4198","BK1191"],"gpt_icon":0},{"id":"2476412959","title":"港股异动 | 欧康维视生物-B(01477)涨超3% 与爱尔康完成股权与产品交割","url":"https://stock-news.laohu8.com/highlight/detail?id=2476412959","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476412959?lang=zh_cn&edition=full","pubTime":"2024-10-18 11:20","pubTimestamp":1729221627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,欧康维视生物-B涨超3%,截至发稿,涨3.72%,报6.14港元,成交额461.25万港元。消息面上,10月17日,欧康维视生物-B宣布,经2024年第一次临时股东大会审议通过,公司与全球眼健康领域的引领者Alcon Inc.成功完成了股权与产品交割。根据协议,欧康维视从爱尔康获得了8款产品组合在中国的研发、制造和商业化领域的相关权益。通过收购这些产品,欧康维视预计将能够提供更全面和先进的治疗方案,进一步满足患者需求并扩大市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4534","BK1574","LU1804176565.USD","LU2265009873.SGD","ALC","01477","BK4198"],"gpt_icon":0},{"id":"2476119276","title":"欧康维视生物与爱尔康完成股权与产品交割 携手共拓眼科医疗蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2476119276","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476119276?lang=zh_cn&edition=full","pubTime":"2024-10-17 16:28","pubTimestamp":1729153738,"startTime":"0","endTime":"0","summary":"2024年10月17日,欧康维视生物宣布,经2024年第一次临时股东大会审议通过,公司与全球眼健康领域的引领者Alcon Inc.成功完成了股权与产品交割。根据协议,欧康维视从爱尔康获得了8款产品组合在中国的研发、制造和商业化领域的相关权益。作为此次交易的对价,欧康维视向爱尔康发行了139,159,664股股份,占总股本的16.71%,至此爱尔康成为欧康维视的最大股东之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=vW1VQ8lthd0%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1804176565.USD","BK4198","BK4534","ALC","LU2265009873.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alcon.com","stockEarnings":[{"period":"1week","weight":-0.026},{"period":"1month","weight":-0.0057},{"period":"3month","weight":-0.0002},{"period":"6month","weight":0.0428},{"period":"1year","weight":-0.0226},{"period":"ytd","weight":0.0246}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1896},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.0648}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alcon Inc.最初于1971年在瑞士注册成立。Alcon是一家以研发为主导的全球医疗专业公司,主要专注于眼部护理。该公司开发,生产和销售药品,手术设备和设备以及消费者眼部护理产品。该公司广泛的产品系列是眼科行业中最强大的产品组合之一,在所有主要产品类别中都拥有高质量和技术先进的产品。该公司相信它拥有全球任何公司眼科研究和开发的最大承诺。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.023619},{"month":2,"riseRate":0.666667,"avgChangeRate":0.007517},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.011579},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.000202},{"month":5,"riseRate":0.571429,"avgChangeRate":0.039015},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.000023},{"month":7,"riseRate":0.714286,"avgChangeRate":0.031633},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002678},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.039338},{"month":10,"riseRate":0.5,"avgChangeRate":-0.010311},{"month":11,"riseRate":0.5,"avgChangeRate":0.027534},{"month":12,"riseRate":0.666667,"avgChangeRate":0.0242}],"exchange":"NYSE","name":"Alcon Inc","nameEN":"Alcon Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alcon Inc(ALC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alcon Inc(ALC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alcon Inc,ALC,Alcon Inc股票,Alcon Inc股票老虎,Alcon Inc股票老虎国际,Alcon Inc行情,Alcon Inc股票行情,Alcon Inc股价,Alcon Inc股市,Alcon Inc股票价格,Alcon Inc股票交易,Alcon Inc股票购买,Alcon Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alcon Inc(ALC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alcon Inc(ALC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}